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Involvement of the pRb/pl6/cdk4/cycin Dl pathway in the tumorigenesis
of sporadic malignant melanomas
GM Me1andsmol, VA Florenes', E Hovig', T 0yjord', 0 Engebraaten', R Holm3, A-L Borresen2
and 0 Fodstad'
Departments of'Tumour Biology, 2Genetics and 3Pathology, Institutefor Cancer Research, The Norwegian Radium Hospital, 0310
Oslo, Norway.
Summary Biopsies from 61 sporadic metastatic malignant melanomas and five melanoma cell lines were
examined for homozygous deletions and mutations in the CDKN2 gene (p16). As the p16 protein is involved in
a cell cycle regulatory pathway consisting of at least pRb, cdk4 and cyclin DI, the tumours were also screened
for amplifications of the last two genes. Moreover, the transcript levels of the genes were determined and the
results compared with the immunohistochemically assessed expression of pRb. Altogether, homozygous
deletions of CDKN2 were found in seven tumours (11%) and two of five cell lines, whereas a mutation was
detected in only one biopsy, indicating that in sporadic melanomas the former mechanism is predominant for
inactivating this gene. Notably, in total 59% of the metastatic lesions lacked detectable expression of p16
mRNA, whereas all the biopsies were found to express pRb. In accordance with the postulated negative
feedback loop between p16 and pRb, one melanoma cell line showed overexpression of CDKN2 mRNA
together with very low levels of the Rb protein. Amplification of the other two genes may not be important in
the tumorigenesis of melanomas, as only one CDK4 and no CCNDI amplification was observed. However,
highly elevated CDK4 mRNA levels, compared with that seen in a panel of normal tissues, were observed in
76% of the tumours, accompanied in 71% of the cases by high expression of the CCNDI cyclin activator.
Although a low frequency of CDKN2 DNA aberrations was observed, the high number of tumours that lacked
CDKN2 expression but showed overexpression of CDK4 and/or CCNDJ, suggest that functional inactivation
of pRb through this pathway may be involved in the development or progression of sporadic human
melanomas.
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The orderly progression of cells through the cell cycle
depends on a finely tuned balance between the levels of
activated cyclins and cyclin-dependent kinases that provide
positive growth signals, and kinase inhibitors that suppress
these effects (Hunter and Pines, 1994; Kamb, 1995). The
newly identified putative tumour-suppressor gene CDKN2,
localised to chromosome fragment 9p2i (Kamb et al., 1994a;
Nobori et al., 1994), encodes an inhibitor (p16) of the cyclin-
dependent kinase 4 (cdk4). This chromosomal region has
been shown to contain cytogenetic abnormalities in several
types of cancer (Fountain et al., 1992; Cairns et al., 1994b),
and linkage analysis of 11 families with multiple cases of
cutaneous malignant melanoma indicated a locus for familial
melanoma susceptibility in this region (Cannon-Albright et
al., 1992). Point mutations and homozygous deletions of the
CDKN2 gene have been detected in 75% (74/99) of all human
melanoma cell lines examined (Kamb et al., 1994a; Liu et al.,
1995), and also in a high percentage of cell lines derived from
tumours of various other histological types (Nobori et al.,
1994). Furthermore, methylation of the 5' CpG island has
been suggested as an alternative mechanism for inactivation
of the gene (Merlo et al., 1995).
p16 was originally identified during a search for proteins
associated with cdk4 (Serrano et al., 1993). When activated
by cyclin Dl, cdk4 is able to phosphorylate the retinoblas-
toma tumour-suppressor protein (pRb) leading to release of
associated proteins that have the capability to activate genes
necessary for cell progression through the G1 phase
(Weinberg, 1995). An imbalance in the cell cycle regulatory
pathway involving p16, cdk4, cyclin Dl and pRb may
therefore result in a cell growth advantage and eventually
lead to tumorigenesis.
The CDK4 gene is localised to human chromosome
segment 12ql3-14, and is frequently amplified and/or
overexpressed in different cancer types, such as sarcomas
(Khatib et al., 1993; Forus et al., 1994) and glioblastomas
(Reifenberger et al., 1994). The CCNDJ (cyclin DI) gene,
localised to chromosome 1q13, was originally identified as a
gene (PRADI) rearranged in parathyroid adenomas, and was
also found activated in B-cell lymphomas harbouring the
(11;14) translocation (Motokura and Arnold, 1993). Ampli-
fication and/or overexpression of this gene has been observed
in breast and squamous cell carcinomas (Lammie et al., 1991;
Jiang et al., 1992; Buckley et al., 1993). Moreover, recent
transfection studies demonstrated that CCNDI may function
as a cooperating oncogene in the malignant transformation of
cells (Hinds et al., 1994). Finally, it is well known that
inactivation of both alleles of the RBI gene is an essential
step in the aetiology of retinoblastoma tumours (Goodrich
and Lee, 1993), and that it is inactivated by somatic
mutations in a high number of osteosarcomas (Wadayama
et al., 1994) and small-cell lung carcinomas (Horowitz et al.,
1990).
Some evidence exists for the involvemnent of p16 in
the tumorigenesis of the familial form of malignant
melanoma (Hussussian et al., 1994; Kamb et al., 1994b;
Ohta et al., 1994; Ranade et al., 1995), and a recent
report (Reed et al., 1995) suggested a correlation between
loss of detectable p16 protein expression and progression
of sporadic cases of this malignancy. The aim of the
present work was to examine the overall frequency of
gene aberrations involving CDKN2, CDK4 and CCNDJ in
a panel of sporadic, metastatic melanomas. In order to
examine to what extent the DNA status was reflected at
the mRNA level, and whether aberrant expression could
be observed in tumours without detectable gene abnorm-
alities, the transcript levels of the three genes were
determined. Finally, we looked for a possible relationship
between these mRNA levels and the expression of the
pRb protein.
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Materials and methods
Specimens
Fresh tumour tissue was obtained from distant metastases of
61 patients with sporadic malignant melanoma. In addition,
five benign melanocytic naevi, four basal cell carcinomas and
a panel of 12 normal tissue samples obtained from kidney,
colon, liver, salivary gland, brain, lung, placenta, striated
muscle, breast gland, ovary, skin (mixture of dermis and
epidermis) and mononucleated cells from peripheral blood,
were studied. Immediately after surgery, the tumour tissue
was frozen in liquid nitrogen and subsequently stored at
-135'C. Formalin-fixed, paraffin-embedded or frozen tissue
sections of melanoma metastasis were obtained from 57 of
the patients. Twenty-eight of the tumours originated from
primary tumours classified as superficial, 17 as nodular, three
belonged to other histological subgroups and in 13 cases the
morphological type was unknown. In addition, five human
melanoma in vitro cell lines (FEMX, HHMSX, LOX, SESX
and THX) were analysed, all established from lymph node
biopsies obtained from patients with metastatic malignant
melanoma treated at The Norwegian Radium Hospital.
Southern blot analysis
Genomic DNA from melanoma tissue was isolated by
standard methods (Maniatis et al., 1982). Aliquots (7 rg) of
DNA were digested with Hindlll, separated on 0.8% agarose
gels and transferred by alkaline blotting onto Hybond N+
membranes (Amersham, UK). After ultraviolet cross-linking
for 5 min, the blots were prehybridised for 2 h and
subsequently hybridised with DNA probes labelled with 32p
by the random primer technique (Feinberg and Vogelstein,
1983). The hybridisation was carried out in 50% formamide,
6 x standard saline citrate (SSC) (20 x SSC = 3.0 M sodium
chloride, 0.3 M sodium citrate), 0.5% sodium dodecyl
sulphate (SDS), 1.5 x Denhardt's (50 x Denhardt's= 1%
Ficoll, 1% bovine serum albumin, 1% polyvinylpyrroli-
done) and 100 jug ml-l denatured salmon sperm DNA at
42°C overnight as described by Maniatis et al. (1982). After
hybridisation, the membranes were washed for 20 min at
65°C subsequently in 2 x SSC/0.5% SDS, 1 x SSC/0.5% SDS
and 0.5 x SSC/0.5% SDS. For multiple hybridisations, the
bound probe was removed by incubating the filters for
15 min at room temperature in 100 mM sodium hydroxide
and 1 mm sodium EDTA.
Samples with signals less than 25% of that from a
reference lane (normal leucocytes) were scored as having a
homozygous deletion of the corresponding gene. This level
was chosen to prevent the possibility that signals caused by
infiltrating normal cells could preclude scoring, but it may
cause underestimation. A signal at least 3-fold more intense
than signals from samples with a normal copy number of the
gene was scored as an amplification. This should eliminate
false positives owing to technical variation in the assays, but
may also be a cause of underestimation. Densitometric
analysis of the autoradiograms (Molecular Dynamics
computing densitometer) was used to determine the signal
intensities in cases that were not clearly altered. To adjust for
unequal amounts of loaded DNA, the blots were rehybridised
with a control probe encoding apolipoprotein B, located to
chromosome 2.
CDGE mutation analysis
DNA from the tumours and cell lines were analysed for point
mutations in the CDKN2 gene using the CDGE method
(constant denaturant gel electrophoresis) (Hovig et al., 1991).
All PCR reactions were performed by mixing 100 ng template
DNA in a buffer containing 10 mM Tris-HCl (pH 8.6),
50 mM potassium chloride, 1.5 mM magnesium chloride,
0.2 mM each dNTP, 50 pmol each primer and 0.5 units Taq
polymerase (Gibco-BRL, Roskilde, Denmark) in a total
volume of 50 ul.
Primersfor amplifyingfrom codon 5 to intron 1 (49 bases 3' of
exon 1), screening codon 20-50 of exon I CDKN2-ex1-U,
5'-CGCCCGCCGCGCCCCGCCCGTCCCGCCGCCCCC-
GCCGGGGAGCAGCATGGAGCCT-3'; CDKN2-exl-L, 5'-
AGTCGCCCGCCATCCCCT-3'.
PCR conditions: Amplification in buffer containing 12%
DMSO by incubating at 94°C for 45 s, 64°C for 30 s and
72°C for 45 s over 30 cycles.
CDGE conditions: 56% denaturant at 60°C, 80 V, for
140 min.
Primersfor amplifyingfrom intron 1 (56 bases 5' ofexon 2) to
codon 106, screening codon 51-96 in exon 2: CDKN2-ex2-
Ul, 5'-CTTCCTTTCCGTCATGCC-3', CDKN2-ex2-L1, 5'-
CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCC-
GCCCCGCACGTCCAGCCGCGCCCC-3'.
PCR conditions: Amplification in buffer containing 12%
DMSO by incubating at 94°C for 75 s, 56°C for 75 s and
72°C for 60 s over 35 cycles.
CDGE conditions: 62% denaturant at 60°C, 80 V, for
150 min.
To increase the region that could be scored for mutations
a BglI restriction digest was performed permitting analysis of
the sequence from codon 60 to codon 96. After the BglI
digest the PCR products were analysed by a second CDGE
performed with 62% denaturant. The gels were run at 60°C,
80 V, for 150 min.
Primersfor amplifyingfrom codon 91 to intron 2 (23 bases 3'
ofexon 2), screening codon 94-152 in exon 2: CDKN2-ex2-
U2, 5'-CGCCCGCCGCGCCCCGCGCCCGTCCCGCCG-
CCCCCGCCCGGACACGCTGGTGGTGCTG-3'. CDKN2-
ex2-L2, 5'-TTCTCAGATCATCAGTCC-3'.
PCR conditions: 35 cycles of 94°C for 75 s, 56°C for 75 s
and 72°C for 60 s.
CDGE conditions: 56% denaturant at 56°C, 130 V, for
180 min.
All gels were stained in SYBR green I nucleic acid gel
stain (Molecular Probes, Eugene, OR, USA). Samples that
showed aberrantly migrating bands by CDGE, indicating
mutations, were submitted to a PCR/sequencing reaction
initiated by the 5'-PCR primer and subsequently sequenced
directly using the Ampli cycle sequencing kit (Perkin-Elmer,
Norwalk, CT, USA).
Northern blot analysis
Total cellular RNA was prepared by the guanidiniumthio-
cyanate-caesium chloride method described by Maniatis et
al. (1982). Samples of 5 ,ug of total RNA were separated by
1% agarose-formaldehyde gel electrophoresis and blotted
onto Hybond N+ membranes (Amersham, UK). After
baking for 2 h and subsequent ultraviolet cross-linking, the
filters were hybridised with DNA probes labelled with 32P as
for Southern blot analysis. The hybridisations were carried
out in 0.5 M sodium phosphate (pH 7.2), 7% SDS and
1 mm sodium EDTA at 65°C overnight as described by
Church and Gilbert (1984). The membranes were subse-
quently washed three times for 15 min in 40 mM sodium
phosphate (pH 7.2) and 1% SDS at 65°C. For multiple
hybridisations the bound probe was removed by incubating
the filters twice for 5 min in 0.1 x SSC, 0.1% SDS, at 95-
100°C.
To correct for uneven amounts of RNA loaded in each
lane, the filters were rehybridised with a kinase-labelled
(Maniatis et al., 1982) oligonucleotide probe specific forpRb/pl6/cdk4/cyclin DI in sporadic melanomas
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human 18S rRNA. The mRNA expression levels were
classified as follows: -/+, undetectable/low expression,
+ + and + + +, high or very high expression.
Immunohistochemical analysis
Sections of formalin-fixed, paraffin-embedded tissue or of
frozen tissue were immunostained using the avidin-
peroxidase complex method described by Hsu et al. (1981).
The paraffin-embedded sections were deparaffinised, treated
with 0.3% hydrogen peroxide in methanol to block
endogenous peroxidase, and microwaved in 10 mM citrate
buffer (pH 6.0) to unmask the epitopes (Cattoretti et al.,
1992). The frozen sections were thawed at room temperature
and fixed for 10 min in 4% buffered formaline. Subse-
quently, the paraffin-embedded or frozen sections were
incubated with normal goat serum to eliminate non-specific
staining. The sections were then incubated for 18-22 h at
4°C with a polyclonal pRb antibody (C-15, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) diluted 1: 700,
followed by sequential incubations with biotin-labelled
secondary antibody and avidin-biotin-peroxidase complex
(Vector, Burlingame, CA, USA). The reaction was finally
developed using diaminobenzidine as chromogen. All series
included positive controls. In addition to tumour samples
from patients with retinoblastoma, negative controls
included incubation with polyclonal anti-pRb preabsorbed
with pRb antigen (1 4ug per ml antibody) (Santa Cruz
Biotechnology). All controls gave satisfactory results. In
accordance with Xu et al. (1991), a tumour was considered
as pRb-negative if every tumour cell lacked pRb nuclear
staining, and pRb-positive if there was any sign of nuclear
staining.
Western blot analysis
Protein lysates were prepared according to standard methods.
Total protein (30 4g) from each sample was separated by 7%
SDS-polyacrylamide gel electrophoresis (Maniatis et al.,
1982) and transferred by semidry blotting onto Immobilon-P
membranes (Millipore Corporation, Bedford, MA, USA). As
a loading and transfer control the membranes were stained
with 0.1% naphthol blue black (Sigma, St Louis, MO, USA).
The membranes were subsequently blocked by phosphate-
buffered saline (PBS) containing 5% dry milk and incubated
for 1 h at room temperature with a monoclonal pRb
antibody (PharMingen, San Diego, CA, USA) diluted
1:5000. After washing, the immunoreactive proteins were
visualised using horseradish peroxidase-conjugated rabbit
anti-mouse antibody (Dako, Glostrup, Denmark) diluted
1: 2000 and the ECL Western blotting detection system
(Amersham, UK).
__
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Probes
The following probes were used: CCNDJ cDNA kindly
provided by Dr D Beach, Howard Hughes Medical Institute,
Cold Spring Harbor, NY, USA, and CDK4 cDNA by Dr P
Meltzer, National Institutes of Health, Bethesda, MD, USA.
As probe for CDKN2 a 929 bp PCR product was used,
amplified from a plasmid encoding the CDKN2 cDNA (Dr D
Beach) (Serrano et al., 1993) with primers suggested by
Kamb et al. (1994a). The APOB clone pB27 obtained from
Dr J Breslow, Rockefeller University, New York, USA, and
a human-specific oligonucleotide probe complementary to
nucleotides 287 to 305 of 18S rRNA were used as control
probes for the Southern and Northern blots respectively.
Results
DNA abnormalities in CDKN2, CDK4 and CCND1
DNA from metastatic lesions of 61 patients with sporadic
malignant melanoma and from five melanoma cell lines were
analysed for abnormalities in the putative tumour-suppressor
gene CDKN2. Homozygous deletions were found in seven
metastatic lesions (11%) and in two of five cell lines (Table I
and Figure 1). The homozygously deleted samples represent
five superficial (5/28 = 18%) and two nodular (2/17 = 12%)
tumours. Fifty of the patient specimens were examined for
gene mutation by the CDGE method covering codon 20-50
in exon 1 and 51-152 in exon 2. One sample (hso) with a
mutation in codon 151 (CCC-.TCC), causing an amino acid
substitution from proline to serine (Table I and Figure 2),
and one sample (aga) with a silent mutation in codon 37
(CTG-.TTG) were found. In addition, the CDGE analysis
revealed two tumours containing the previously reported
(Cairns et al., 1994a; Spruck et al., 1994; Sun et al., 1995)
polymorphic G-.A substitution (Ala-.Thr) in codon 148. No
point mutations were observed in the cell lines.
In parallel, the melanoma panel was analysed for
amplification of the functionally related genes CDK4 and
CCNDI (Table I and Figure 1). Only one tumour was found
to have an amplified CDK4 gene, whereas CCNDJ was not
affected in any of the melanoma metastases and cell lines.
RNA expression levels of CDKN2, CDK4 and CCND1
To examine the association between the DNA status and the
gene expression at the mRNA level, total RNA was extracted
from 51 of 61 tumours (25 superficial, 13 nodular, three
belonged to other histological subgroups and ten were not
classified), and from the five cell lines. RNA from five benign
naevi and 12 different normal tissue samples were used as
controls.
Table I Tumours with DNA' deletion, mutation or amplification affecting either
CCNDI genes and relationship to the mRNA levelsb
of the CDKN2, CDK4 or
Patient CDKN2 CDK4 CCNDI
no. DNA mRNA DNA mRNA DNA mRNA
obr D - N + + + N + + +
ggu D - N + N + +
emh D - N + + N +
asn D - N + + + N (+)
sra D - N + + N + +(+)
kwa D - N + + N + + +
mob D - N + + N + + +
hso M ND N ND N ND
nak N + A + + + N + +
LOXC D - N + + N + +(+)
SESXC D - N + + N + +
No. of tumours 9 1 0
with DNA
alterationsd
aN,normal; D, deletion; A, amplification; M,pointmutation; ND, notdetermined.bExpression levelsasdescribedin
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Figure 1 Representative Southern blot analysis demonstrating
the DNA status of CDKN2, CDK4 and CCNDI in tissue
obtained from human metastatic melanomas (aga, kcl, lae, obr,
ggu), from melanoma cell lines (LOX, THX) and from human
leucocytes. The DNA (7,ug in each lane), digested with HindIII,
was subsequently hybridised with probes encoding the three
different genes and, as a control, with an APOB probe. Two
additional bands emerged in the kcl tumour when hybridising
with the APOB probe, probably due to a polymorphic site.
Samples with homozygous deletion of CDKN2, scored as
described in Materials and methods, are indicated by a D
(deletion) below the corresponding panel.
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Figure 2 Direct sequencing of the CDKN2 gene. The left panel
shows the sequence observed in the hso tumour harbouring a
mutation in codon 151 (CCC-+TCC), while the right panel
demonstrates the normal sequence.
In general, the melanomas demonstrated low levels of
CDKN2 mRNA (Figure 3). Altogether 30 of the tumours
(59%) lacked detectable expression of the inhibitor gene, as
also was the case in benign naevi, basal cell carcinomas and
normal skin tissue. Twenty-four of the tumours with no
detectable CDKN2 expression showed high transcript levels
of either the kinase, CDK4, or the kinase activator, CCNDJ.
As expected, none of the samples with homozygous deletion
of CDKN2 expressed the gene, whereas all seven cases
showed high mRNA levels of either of the other genes (Table
I). The three tumours containing a polymorphic site in
CDKN2 demonstrated low/undetectable levels of the corre-
sponding mRNA (exemplified by sample aga in Figure 3).
RNA was not available from the tumour with mutation in
Figure 3 Northern blot analysis demonstrating the mRNA levels
of CDKN2, CDK4 and CCND1, for the same cases as listed in
Figure 1, except that lane 8 contains RNA from a benign naevus.
Total RNA (5 jg) applied in each lane was subsequently
hybridised with probes encoding the three genes, and with an
18S rRNA probe as a control.
codon 151. Only nine samples (eight tumours and one cell
line) showed a high expression of the gene (Table II and
Figure 3). Of the eight tumours with high expression, four
were characterised as superficial (4/25 = 16%), two as nodular
(2/13=15%) and two were from other subgroups. The THX
cell line demonstrated a very high level of CDKN2 mRNA
(Figure 3), and also a similarly elevated transcript level of the
two other genes as was observed in the other cell lines.
The CDK4 mRNA levels were high (+ + or + + +) in 39
of the melanoma patients (39/51 =76%) (Table II) and in 28
of these the high kinase expression was accompanied by
elevated levels of cyclin Dl. The sample with CDK4
amplification expressed a high level of the corresponding
mRNA (Table I). Normal skin and benign naevi expressed
low, but detectable, amounts of CDK4 mRNA, whereas all
cell lines showed high transcript levels of both the kinase and
the activator.
High amounts of cyclin Dl mRNA were observed in 32 of
the malignant melanomas (32/51 =63%) (Table II). In
comparison, four of five benign naevi had low, but
detectable transcript levels, whereas lung and skin were the
only normal tissues that showed high amounts of the mRNA.
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Table H Tumours with high mRNA expression of CDKN2, CDK4 and CCNDI
Source of No. of cases with high (+ +/+ + +) mRNA levelsa
sample No. analysed CDKN2 CDK4 CCNDl
Tumour tissue 51 8 (16%) 39 (76%) 32 (63%)
Cell lines 5 1 (20%) 5 (100%) 5 (100%)
Normal tissues 12 0 4b 2c
aExpression levels as scored in Materials and methods. bHigh expression of CDK4 in kidney, lung,
ovary and breast gland. 'High expression of CCNDI in lung and skin.
LOX THX
Figure 4 Western blot demonstrating pRb expression in human
melanoma cell lines LOX (homozygous deletion of CDKN2) and
THX (high CDKN2 mRNA levels).
Protein expression ofpRb
For immunohistochemical detection of pRb, frozen tissue
sections were available from 15 of the melanoma metastases,
and from 42 additional patients we obtained formalin-fixed
paraffin-embedded sections. Heterogeneous pRb nuclear
staining was identified in all samples, and the tumours were
thus classified as pRb-positive. The phosphorylation status of
the protein has not been examined in the patient material,
but it is not inconceivable that the few patients showing high
levels of the kinase inhibitor simultaneously express the
phosphorylated form of the Rb protein.
The melanoma cells lines, however, were examined by
Western blot analysis in order to determine the pRb status.
The THX cell line, showing remarkably high expression of
the CDKN2 mRNA (Figure 3), expressed small/undetectable
amounts of pRb (Figure 4), also confirmed by immunohis-
tochemical detection on cytospins (results not shown). In
contrast, the four other cell lines examined, two demonstrat-
ing homozygous loss of CDKN2, all expressed both the
activated and the inactivated form of the Rb protein
(exemplifed by the LOX cell line in Figure 4).
Discussion
The present study of 61 biopsied metastases from sporadic
melanoma metastases revealed abnormalities in the CDKN2
gene in 13% of the cases. Thus, seven patients had
homozygous deletions of the gene and one patient had a
point mutation in codon 151. This frequency is in agreement
with what has been reported previously on homozygous
deletions in uncultured material from other tumour types
(Cairns et al., 1994b; Spruck et al., 1994). Moreover, that
only one point mutation was detected in our material is in
agreement with what Ohta et al. (1994) reported. This
frequency is, however, somewhat lower than that observed
by Gruis et al. (1995), and furthermore, far lower than has
been reported for cell lines. Also, in a total of five human
melanoma cell lines examined we found no point mutations,
but two homozygous deletions. Notably, our analysis
demonstrated that homozygous deletion seems to be the
predominant mechanism for inactivating the CDKN2 gene in
tumour biopsies, as has been reported for most tumour cell
lines, including melanoma lines (Kamb et al., 1994a; Gruis et
al., 1995; Liu et al., 1995).
The low incidence of CDKN2 deletions in our material
compared with that observed in cell lines may be explained in
part by methodological factors. Despite careful dissection of
the tumour tissue before freezing, infiltration of normal cells
in the tumour biopsy could result in an underestimation of
the number of homozygous deletions observed in the
melanoma patients. Southern blot analysis, however, as used
here to detect homozygous deletions, appears to be somewhat
less sensitive to a contribution from a moderate number of
normal cells in the DNA preparation compared with PCR-
based techniques. The difference in deletion frequency
observed in cell lines compared with tumour biopsies might
conceivably be a result of in vitro cell cultivation, as
homozygous loss of CDKN2 may provide additional growth
advantage to cells in culture.
The PCR-based CDGE analysis has been shown to detect
mutations, visualised by SYBR green I staining, if present in
at least 10% of the cells when analysing homoduplex and
down to 1% when analysing heteroduplex separation
(B0rresen, 1996). This indicates that it is unlikely that
contaminating normal cell DNA should prevent the
detection of mutant DNA. Our mutation analysis covers
approximately 85% of the coding sequence (codon 20-152),
and the possibility therefore exists that some mutations may
not have been detected in the 5'-end of the gene. It should be
noted, however, that by examining a mutation spectrum of 72
reported CDKN2 mutations detected in different types of
cancer, it was found, in contrast to that reported for tumour
cell lines (Liu et al., 1995), that the N-terminus seems to be
less exposed to mutations (B Smith-S0rensen, personal
communication). In fact, all tumour-associated CDKN2
mutations so far reported are included in the sequences
screened in this study.
In contrast to the mutation spectrum of CDKN2 in non-
skin malignancies, a remarkably high frequency of typical
UV-induced CC-.TT transitions has been observed in
melanoma cell lines, reflecting a role of ultraviolet radiation
in the generation of sporadic melanoma (Liu et al., 1995;
Pollock et al., 1995). It is conceivable that UV-induced
mutations may be selected for during in vitro cultivation.
Furthermore, the codon 151 mutation observed in the hso
tumour biopsy also falls into this group of mutations.
Interestingly, the tumour named hso with mutated CDKN2
was previously shown to harbour a mutated TP53 gene
(Fl0renes et al., 1994), but the TGT-*TGG transversion in
codon 275 of TP53 is probably not induced by UV radiation.
Several reports have demonstrated tumour samples harbour-
ing mutations in both these genes, suggesting that the
product of the tumour-suppressor genes functions in distinct
pathways (Gruis et al., 1995; Aagaard et al., 1995).
It is important to regard p16 as a member of a cell cycle
regulatory pathway involving at least three other gene
products, namely: pRb, cdk4 and cyclin Dl. pRb is the
main mediator of growth suppression in this pathway, and
the tumour-promoting effects of aberrations involving p16,
cdk4 and cyclin Dl are most likely due to influence on the
phosphorylation of the retinoblastoma protein. This mechan-
ism for functional inactivation of pRb can involve increased
kinase activity, caused either by loss ofp16 inhibitor function
or by overexpression of the kinase or the cyclin Dl activator.
p16 is suggested to functional as a negative regulator of cdk4
activity once pRb has been inactivated by phosphorylation,
and p16-induced growth suppression has been demonstrated
in cells containing a functional pRb (Koh et al., 1995; Lukas
et al., 1995; Medema et al., 1995; Serrano et al., 1995).pRb/pl6/cdk4/cycin DI in sporadic melanomas
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Moreover. in cells harbouring a constitutively inactivated Rb
protein. elevated p16 expression concomitant with inhibition
of the kinase activity has also been detected (Serrano et al..
1993). However. in such cells overexpression of p16 does not
induce cell cycle arrest. probablv due to the fact that Rb
represents the major target protein and is required as a
downstream effector in p16-mediated growth arrest (Koh et
al.. 1995: Lukas et al.. 1995: Medema et al.. 1995: Serrano et
al.. 1995).
In agreement with other studies (Serrano et al.. 1993: Li et
al.. 1994: Tam et al.. 1994a; Yeager et al.. 1995) showing
correlation between high expression of p16 and absence of
functional Rb protein. we found in our panel of metastatic
melanomas only nine tumours (17%) With high levels of p16
mRNA. All the examined cases expressed the Rb protein as
detected by immunohistochemistry. a finding consistent with
the low frequency of pRb deficiency observed in melanomas
(Horowitz et al.. 1990: Lewis et al.. 1993). It is conceivable
that the Rb protein might be inactivated by phosphorylation
in the few tumours showing high inhibitor expression.
Among the cell lines. high levels of both phosphorvlated
and unphosphorylated pRb were detected in those lacking
CDKAN. whereas in one cell line overexpression of CDKN2
mRNA was accompanied With low or nearly undetectable
levels of pRb.
That a high fraction of metastatic melanomas did not
express detectable levels of CDKV2 mRNA (60%) is in
agreement with recent results (Reed et al.. 1995). demonstrat-
ing loss of p16 protein expression in metastatic lesions (44%).
but not in primary melanomas. melanomas in situ and
atypical naeVi. The mechanism by which loss of p16
expression. without homozygous deletion, is associated with
invasiveness and progression of malignant melanomas is still
unclear. Functional inactivation of the CDKN2 gene by
hypermethylation of the 5' CpG island has been demon-
strated in cell lines and biopsies of non-small-cell lung
carcinomas (Merlo et al.. 1995: Otterson et al.. 1995).
Whether de nowo methylation plays a role in controlling the
expression of this gene in sporadic melanoma lesions has not
yet been examined.
Notably. the melanomas showed very high levels of CDK4
mRNA. often accompanied with high expression of cyclin
Dl. Amplification of both these genes has been found in
different cancer ty-pes (Lammie et al.. 1991: Khatib et al..
1993: Mxlandsmo et al.. 1995). but seems to be a rare event
in the development of metastatic malignant melanomas. as no
CC.NDJ amplification and only one CDK4 amplification was
observed. Tumour-associated overexpression of cycin Dl.
without any observed amplification of the gene. has
previously been reported in primary malignant melanomas
(Bartkova et al.. 1995). Recently. a somatic point mutation in
the CDK4 gene was demonstrated in a human melanoma.
disrupting the interaction bettween the kinase and the p16
inhibitor (W6lfel et al.. 1995). It is believed that such
mutations may constitute a new mechanism to inactivate this
regulatory pathway in some tumour cells. Moreover. He et al.
(1994) suggested overexpression of cdk4 in excess of what can
be inactivated by p16. as an alternative mechanism for
suppressing pRb growth control in glioma cell lines.
However, the relative abundance of D-type cycins and p16
determine the cdk4 activity, and it has been demonstrated
that synthesis of cycin DI. a protein with short half-life. is
necessary and rate-limiting for GI progression (Matsushime
et al.. 1991; Baldin et al.. 1993). According to this. it has been
postulated that tumour cells can obtain a growth advantage
from a moderate overexpression of D-type cycins and or
from a more massive overexpression of the catalytic subunit
(Tam et al.. 1994b). That all the melanoma biopsies were
from metastases. often aggressive tumours with high
proliferation rates, may provide a reasonable explanation
for the observed high expression levels. However, it should be
noted that no significant association between high cycin Dl
expression and prognostic factors, such as relapse-free period
and tumour thickness. was revealed (not shown).
Several recent reports suggest that disturbance of a single
growth regulatory pathway, resulting in an inactivation of
pRb function, is of significant importance in the development
of different types of cancer. Alterations of any of the
components in the pathway constituted by pI6, pRb, cycin
Dl and cdk4 may be sufficient to create an imbalance in the
system, thereby providing the cells with a growth advantage.
Although the frequency of CDKN2 gene aberrations was
found to be low in our panel of malignant melanomas. we
observed a high number of metastatic lesions without
CDKV2 mRNA expression together with overexpression of
CDK4 and CCNDJ. Altogether the results may indicate that
functional inactivation of pRb is involved in the tumonigen-
esis of sporadic. malignant melanomas.
Abbreviations
CDK4. cyclin-dependent kinase 4: CDKN2. the cdk4 inhibitor.
p16: CCNDL. cyclin Dl; pRb. the retinoblastoma protein: APOB.
apolipoprotein B: SDS. sodium dodecyl sulphate; SSC. standard
saline citrate: PCR. polymerase chain reaction: CDGE. constant
denaturant gel electrophoresis.
Acknowledgements
We thank Frode Knstiansen. Gunn Elin Trones. Turid Melling-
sater. Sin' Juell. Anne Forus. Ellen Hellesvlt. Mette My-re and
Hilde Johnsen for excellent technical assistance. Birgitte Smith-
Sorensen for generating the p16 mutation spectrum and Frances
Jaques for her secretarial assistance. This work was supported by
The Norwegian Cancer Society and the Anders Jahre Foundation.
References
AAGAARD L. LUKAS J. BARTKOVA J. KJERULFF AA. STRAUSS M
AN-D BARTEK J. (1995). Aberrations of p1l,ink4 and retinoblas-
toma tumour-suppressor genes occur in distinct sub-sets of
human cancer cell lines. Int. J. Cancer. 61, 115-120.
BALDIN- V. LUKAS J. MARCOTE M. PAGANO M AN-D DRAETTA G.
(1993). Cy-clin Dl is a nuclear protein required for cell cycle
progression in G1. Genes Dev.. 7, 812-821.
BARTKOVA J. LUKAS J. STRA-USS M AND BARTEK J. (1995). Cy-clin
Dl oncoprotein aberrantly accumulates in malignancies of
div-erse histogenesis. Oncogene. 10, 775- 778.
BORRESEN AL. (1996). Constant denaturant gel electrophoresis
(CDGE) in mutation screening. In Technologies for Detection of
DN-.4 Damage and Mutations. Pfeifer GP (ed). Plenum Press (in
press).
BUCKLEY MF. SWEENEY KJ. HAMILTON JA. SINI RL. MA-NNING
DL. N-ICHOLSON RI. DEFAZIO A. WATTS CK. MUSGROVE EA
AND SUTHERLAND RL. (1993). Expression and amplification of
cyclin genes in human breast cancer. Oncogene. 8, 2127-2133.
CAIRNS P. M-AO L. MERLO A. LEE DJ. SCHWAB D. EBY Y. TOKINO
K. RIET PVD. BLAUGRUND JE AND SIDRANSKY D. (1994a).
Rates of p16 (MTSI) mutations in prnmarv tumors with 9p loss.
Science. 265, 415 -416.
CAIRNS P. TOKINO K. EBY Y AND SIDRANSKY D. (1994b).
Homozvgous deletions of 9p21 in primary human bladder
tumors detected by comparative multiplex polmerase chain
reaction. Cancer Res.. 54, 1422- 1424.
CAN7NON-ALBRIGHT LA. GOLDGAR DE. MEYER LJ. LEWIS CM.
AN-DERSON DE. FOLNTA.N' JW. HEGI ME. WISEMAN RW.
PETTY EM. BALE AE. OLOPADE 01. DIAZ MO. KWIATKOWSKI
D. PIEPKORN MW. ZONE JJ AND SKOLNICK MH. (1992).
Assignment of a locus for familial melanoma. MLM. to
chromosome 9pI3-p22. Science. 258, 1148 - 1152.pRb/pl6/c4/cycb D in spo -dic m__muom
GM I&a,* et i
915
CATTORETII G, BECKER MH, KEYG, DUCHROW M, SCHLUTERC,
GALLE J AND GERDES J. (1992). Monoclonal antibodies against
recombinant parts ofthe Ki-67 antigen (MIB 1 and MIB 3) detect
proliferating cells in microwave-processed formalin-fixed paraffin
sections. J. Pathol., 168, 357-363.
CHURCH GM AND GILBERT W. (1984). Genomic sequencing. Proc.
Natl Acad. Sci. USA, 81, 1991-1995.
FEINBERG AP AND VOGELSTEIN B. (1983). A technique for radio
labelling DNA restriction endonuclease fragments to high specific
activity. Anal. Biochem., 132, 6-13.
FLORENES VA, 0YJORD T, HOLM R, SKREDE M, BORRESEN A-L,
NESLAND JM AND FODSTAD 0. (1994). TP53 allele loss,
mutations and expression in malignant melanoma. Br. J.
Cancer, 69, 253-259.
FORUS A, FL0RENES V, MAELANDSMO GM, FODSTAD 0 AND
MYKLEBOST 0. (1994). 12ql3-14 amplica in human sarcomas
without MDM2 include CDK4, SAS and GADD153/CHOP.
Cancer Genet. Cytogenet., 77, 200.
FOUNTAIN JW, KARAYIORGOU M, ERNSTOFF MS, KIRKWOOD
JM, VLOCK DR, TITUS-ERNSTOFF L, BOUCHARD B, VIJAYA-
SARADHI S, HOUGHTON AN, LAHTI J, KIDD VJ, HOUSMAN DE
AND DRACOPOLI NC. (1992). Homozygous deletions within
human chromosome band 9p2l in melanoma. Proc. Natl.Acad.
Sci. USA, 89, 10557- 10561.
GOODRICH DW AND LEE WH. (1993). Molecular characterization
ofthe retinoblastoma susceptibility gene. Biochim. Biophys. Acta,
1155, 43-61.
GRUIS NA, WEAVER-FELDHAUS J, LIU Q, FRYE C, EELES R,
ORLOW I, LACOMBE L, PONCE-CASTANEDA V, LIANES P,
LATRES E, SKOLNICK M, CORDON-CARDO C AND KAMB A.
(1995). Genetic evidence in melanoma and bladder cancers that
p16 and p53 function in separate pathways oftumor suppression.
Am. J. Pathol., 146, 1199-1206.
HE J, ALLEN JR, COLLINS VP, ALLALUNIS-TURNER MJ, GODBOUT
R, DAY RSR III ANDJAMESCD. (1994). CDK4 amplification is an
alternative mechanism to p16 gene homozygous deletion in
glioma cell lines. Cancer Res., 54, 5804-5807.
HINDS PW, DOWDY SF, EATON EN, ARNOLD A AND WEINBERG
RA. (1994). Function of a human cyclic gene as an oncogene.
Proc. Natd Acad. Sci. USA, 91, 709- 713.
HOROWITZ JM, PARK SH, BOGENMANN E, CHENG JC, YANDELL
DW, KAYE FJ, MINNA JD, DRYJA TP AND WEINBERG RA.
(1990). Frequent inactivation of the retinoblastoma anti-
oncogene is restricted to a subset of human tumor cells. Proc.
Natl. Acad. Sci. USA, 87, 2775-2779.
HOVIG E, SMITH-SORENSEN B, BROGGER A AND BORRESEN AL.
(1991). Constant denaturant gelelectrophoresis, amodification of
denaturing gradiant gel electrophoresis, in mutation detection.
Mutat. Res., 262, 63-71.
HSU SM, RAINE L AND FANGER H. (1981). A comparative study of
the peroxidase-antiperoxidase method and an avidin-biotin
complex method for studying polypeptide hormones with
radioimmunoassay antibodies. Am. J. Clin. Pathol., 75, 734-738.
HUNTER T AND PINES J. (1994). Cyclins and Cancer II: Cyclin D
and CDK inhibitors come ofage. Cell, 79, 573-582.
HUSSUSLAN CJ, STRUEWING JP, GOLDSTEIN AM, HIGGINS PA,
ALLY DS, SHEAHAN MD, CLARK WH JR, TUCKER MA AND
DRACOPOLI NC. (1994). Germline p16 mutations in familial
melanoma. Nature Genet., 8, 15-21.
JIANG W, KAHN SM, TOMITA N, ZHANG YJ, LU SH AND
WEINSTEIN IB. (1992). Amplification and expression of human
cyclin D gene in esophageal cancer. Cancer Res., 52, 2980-2983.
KAMBA. (1995). Cell-cycle regulators and cancer. Trends Genet., 11,
136-140.
KAMB A, GRUIS NA, WEAVER-FELDHAUS J, LIU Q, HARSHMAN K,
TAVTIGIAN SV, STOCKERT E, DAY RR, JOHNSON BE AND
SKOLNICK MH. (1994a). A cell cycle regulator potentially
involved in genesis ofmany tumor types. Science, 264, 436-440.
KAMB A, SHATTUCK-EIDENS D, EELES R. LIU Q, GRUIS NA, DING
W, HUSSEY C, TRAN T, MIKI Y, WEAVER-FELDHAUS J,
MCCLURE M, AITKEN JF, ANDERSON DE, BERGMAN W,
FRANTS R, GOLDGAR DE, GREEN A, MACCLENNAN R,
MARTIN NG, MEYER LJ, YOUL P, ZONE JJ, SKOLNICK MH
AND CANNON-ALBRIGHT LA. (1994b). Analysis ofthe p16 gene
(CDKNJ2) as a candidate for the chromosome 9p melanoma
susceptibility locus. N'ature Genet., 8, 23-26.
KHATIB ZA, MATSUSHIME H, VALENTINE M, SHAPIRO DN,
SHERR CJ AND LOOK AT. (1993). Coamplification of the CDK4
gene with MDM2 and GLI in human sarcomas. Cancer Res., 53,
5535-5541.
KOH J, ENDERS GH, DYNLACHT BD AND HARLOW E. (1995).
Tumour-derived p16 alleles encoding proteins defective in cell-
cycle inhibition. Nature, 375, 506-510.
LAMMIE GA, FANTL V, SMITH R, SCHUURING E, BROOKES S.
MICHALIDES R, DICKSONC, ARNOLD A AND PETERS G. (1991).
D11S287, a putative oncogene on chromosome IIq13, is
amplified and expressed in squamous cell and mammary
carcinomas and linked to BCL-1. Oncogene, 6,439-444.
LEWIS DC, WARREN N, SHUKLA VK, GRIMSHAW D, LAIDLER P
AND PADUA RA. (1993). Gross rearrangements and deletions of
the retinoblastoma gene are rare in malignant melanoma. Acta
Derm. Venereol., 73, 236.
LI Y, NICHOLS MA, SHAY JW AND XIONG Y. (1994). Transcrip-
tional repression of the D-type cyclin-dependent kinase inhibitor
p16 by the retinoblastoma susceptibility gene product pRb.
Cancer Res., 54, 6078-6082.
LIU Q, NEUHAUSEN S, MCCLURE M, FRYE C, WEAVER-FELDHAUS
J, GRUIS NA, EDDINGTON K, ALLALUNIS-TURNER MJ,
SKOLNICK MH, FUJIMURA FK AND KAMB A. (1995). CDANK2
(MTS) tumor suppressor gene mutations in human tumor cell
lines. Oncogene, 10, 1061-1067.
LUKAS J, PARRY D, AAGAARD L, MANN DJ. BARTKOVA J,
STRAUSS M, PETERS G AND BARTEK J. (1995). Retinoblasto-
ma-protein-dependent cell-cycle inhibition by the tumour
suppressor p16. Nature, 375, 503 -506.
MIELANDSMO GM, BERNER JM, FLORENES VA, FORUS A. HOVIG
E, FODSTAD 0 AND MYKLEBOST 0. (1995). Homozygous
deletion frequency and expression levels of the CDKN2 gene in
human sarcomas-relationship to amplification and mRNA levels
of CDK4 and CCNDI. Br. J. Cancer, 72, 393-398.
MANIATIS T, FRITSCH EF AND SAMBROOK J. (1982). Molecular
Cloning: a Laboratory Manual. Cold Spring Harbor Laboratory
Press: Cold Spring Harbor, NY.
MATSUSHIME H, ROUSSEL RA, ASHMUN RA AND SHERR CJ.
(1991). Colony-stimulating factor 1 regulates novel cyclins during
the Gl phase ofthe cell cycle. Cell, 65, 701 -713.
MEDEMA RH, HERRERA RE, LAM F AND WEINBERG RA. (1995).
Growth suppression by p161k4 requires functional retinoblasto-
ma protein. Proc. Natl Acad. Sci. USA, 92, 6289-6293.
MERLO A, HERMAN JG, MAO L, LEE DJ, GABRIELSON E, BURGER
PC, BAYLIN SB AND SIDRANSKY D. (1995). 5' CpG island
methylation is associated with transcriptional silencing of the
tumour suppressor pl6/CDKN2/MTSJ in human cancers. Nature
Med., 1, 686-692.
MOTOKURA T AND ARNOLD A. (1993). Cyclin D and oncogenesis.
Curr. Opin. Genet. Dev., 3, 5-10.
NOBORI T, MIURA K, WU DJ, LOIS A. TAKABAYASHI K AND
CARSON DA. (1994). Deletions of the cyclin-dependent kinase-4
inhibitor gene in multiple human cancers. Nature, 368, 753 -756.
OHTA M, NAGAI H, SHIMIZU M, RASIO D, BERD D, MASTRANGE-
LO M, SINGH AD, SHIELDS JA. SHIELDS CL, CROCE CM AND
HUEBNERK. (1994). Rarity ofsomatic and germline mutations of
the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in
melanoma. Cancer Res., 54, 5269-5272.
OTlTERSON GA, KHLEIF SN, CHEN W, COXON AB AND KAYE FJ.
(1995). CDKN2 gene silencing in lung cancer by DNA
hypermethylation and kinetics of pl6'14 protein induction by
5-aza 2' deoxycytidine. Oncogene, 11, 1211 - 1216.
POLLOCK PM, YU F, QIU L, PARSONS PG AND HAYWARD NK.
(1995). Evidence for u.v. induction of CDKN2 mutations in
melanoma cell lines. Oncogene, 11, 663-668.
RANADE K, HUSSUSSIAN CJ, SIKORSKI RS, VARMUS HE. GOLD-
STEIN AM, TUCKER MA, SERRANO M, HANNON GJ, BEACH D
AND DRACOPOLI NC. (1995). Mutations associated with familial
melanoma impair p16 MK4 function. Nature Genet., 10, 114-116.
REED JA, LOGANZO JR F, SHEA CR, WALKER GJ, FLORES JF,
GLENDENING JM, BOGDANY JK, SHIEL MJ, HALUSKA FG.
FOUNTAINJWANDALBINOAP. (1995). Loss ofexpression ofthe
pl6/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in
melanocytic lesions correlates with invasive stage of tumor
progression. Cancer Res., 55, 2713-2718.
REIFENBERGER G, REIFENBERGER J, ICHIMURA K, MELTZER PS
AND COLLINS VP. (1994). Amplification of multiple genes from
chromosomal region 12ql3-14 in huiman malignant gliomas:
preliminary mapping of the amplicons shows preferential
involvement of CDK4, SAS and M{DM2. Cancer Res.. 54,
4299-4303.
SERRANO M, HANNON GJ AND BEACH D. (1993). A new regulatory
motif in cell-cycle control causing specific inhibition ofcyclin D
CDK4. Nature, 366, 704-707.pRb/pl6/cdk4/cycli DI in sporaic mdimas
916GM Andsrno et a
916
SERRANO M. GOMEZ-LAHOZ E, DEPINHO RA, BEACH DAND BAR-
SAGI D. (1995). Inhibition of ras-induced proliferation and
cellular transformation by pj6INK4* Science, 267, 249-252.
SPRUCK III CH, GONZALEZ-ZULUETA M, SHIBATA A, SIMONEAU
AR, LIN M-F. GONZALES F, TSAI YC AND JONES PA. (1994). p16
gene in uncultured tumours. Nature, 370, 183- 184.
SUN Y. HILDESHEIM A, LANIERAE, CAO Y, YAO KT, RAAB-TRAUB
N AND YANG CS. (1995). No point mutation but decreased
expression ofthe pI6/MTSJ tumor suppressor gene in nasophar-
yngeal carcinomas. Oncogene, 10, 785-788.
TAM SW, SHAY JW AND PAGANO M. (1994a). Differential
expression and cell cycle regulation of the cyclin-dependent
kinase 4 inhibitor p16 K4. Cancer Res., 54, 5816-5820.
TAM SW. THEODORAS AM. SHAY XW, DRAETTA GF AND PAGANO
M. (1994b). Differential expression and regulation of cyclin Dl
protein in normal and tumor human cells: association with Cdk4
is required forCyclin Dl function in GI progression. Oncogene, 9,
2663-2674.
WADAYAMA B, TOGUCHIDA J, SHIMIZU T, ISHIZAKI K, SASAKI
MS, KOTOURA Y AND YAMAMURO T. (1994). Mutation
spectrum of the retinoblastoma gene in osteosarcomas. Cancer
Res., 54, 3042-3048.
WEINBERG RA. (1995). The retinoblastoma protein and cell cycle
control. Cell, 81, 323-330.
WOLFEL T, HAUER M, SCHNEIDER J, SERRANO M. WOLFEL C,
KLEHMANN-HIEB E, DE PLAEN E, HANKELN T, MEYER ZUM
BUSCHENFELDE K-H AND BEACH D. (1995). A p16INK4a-
insensitive CDK4 mutant targeted by cytolytic T lymphocytes in
a human melanoma. Science, 269, 1281-1284.
XU HJ, HU SX, CAGLE PT, MOORE GE AND BENEDICT WF. (1991).
Absence of retinoblastoma protein expression in primary non-
small cell lung carcinomas. Cancer Res., 51, 2735-2739.
YEAGER T, STADLER W, BELAIR C, PUTHENVEETTIL J, OLOPADE
0 AND REZNIKOFF C. (1995). Increased p16 levels correlate with
pRb alterations in human urothelial cells. Cancer Res., 55, 493-
497.